RecruitingPhase 2NCT07317206
Ayahuasca, Esketamine and PTSD
Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study
Sponsor
University of Sao Paulo
Enrollment
10 participants
Start Date
Dec 20, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- posttraumatic stress disorder
Exclusion Criteria1
- psychiatric and other medical comorbidities
Interventions
DRUGAyahuasca
oral ayahuasca
DRUGEsketamine
oral esketamine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07317206
Related Trials
LHC-CIDI-5 in Hong Kong
NCT068045251 location
Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders
NCT069378921 location
Augmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD
NCT072381921 location
Efficacy of an EMDR App for PTSD and SUD
NCT071466331 location
Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints
NCT057760563 locations